Key Takeaways RCKT posted Q4 loss of 38 cents per share, beating estimates, while no revenues were reported.Rocket Pharmaceuticals' resubmitted BLA for Kresladi in LAD-I faces an FDA decision on March 28, 2026.RCKT expects cash runway into Q2 2027 as the RP-A501 study in Danon disease resumes in H1 2026.Rocket Pharmaceuticals (RCKT) incurred a loss of 38 cents per share in the fourth quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of 42 cents. In the year-ago quarter, the com ...

CRISPR Therapeutics AG (NASDAQ:CRSP) shares jumped on Thursday, building on its Feb. 13 earnings report that showed growing momentum for its lead gene therapy and a deepening pipeline.Casgevy Revenue Casgevy, the gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia, generated $54 million in the fourth quarter and $116 million for the full-year 2025. A total of 64 patients received infusions in the fourth quarter alone, with 147 initiating treatment through the first cell c ...

Passage Bio (NasdaqGS:PASG) FY Conference February 26, 2026 08:40 AM ET Company ParticipantsWilliam Chou - President and CEOConference Call ParticipantsJay Olson - Managing Director and Senior AnalystJay OlsonHello, everyone, and welcome to Oppenheimer's 36th Annual Life Science Conference. I'm Jay Olson, one of the biotech analysts here at Oppenheimer, and it's a pleasure to welcome you to our discussion with Passage Bio, and it's an honor to introduce William Chou, the President and CEO of Passage. Thank ...

Sarepta Therapeutics (NasdaqGS:SRPT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsBrian Abrahams - Managing Director and Co-Head of Biotechnology Equity ResearchDoug Ingram - President and Chief Executive OfficerIan M. Estepan - VP of Investor RelationsLouise Rodino-Klapac - Executive VP, Chief Scientific Officer, and Head of Research and DevelopmentMichael Yee - Global Head of Biotechnology Equity ResearchPatrick Moss - Executive VP and Chief Commercial OfficerRyan Wong - Interim ...

Sarepta Therapeutics (NasdaqGS:SRPT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsBrian Abrahams - Managing Director and Co-Head of Biotechnology Equity ResearchDoug Ingram - President and Chief Executive OfficerIan M. Estepan - Director of Investor RelationsLouise Rodino-Klapac - Executive VP, Chief Scientific Officer, and Head of Research and DevelopmentPatrick Moss - Executive VP and Chief Commercial OfficerRyan Wong - Interim CFOTazeen Ahmad - Managing DirectorConference Call ...

Sarepta Therapeutics (NasdaqGS:SRPT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker17Good afternoon, welcome to Sarepta's fourth quarter 2025 earnings results call. As a reminder, today's program is being recorded. At this time, I'll turn the call over to Ian Estepan, Sarepta's Director of Investor Relations. Please go ahead.Speaker8Thank you, operator, and thank you all for joining today's call. Earlier this afternoon, we released our financial results for the fourth quarter of 2025. The press ...

REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights [Accessibility Statement] Skip NavigationROCKVILLE, Md., Feb. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 5, at 8:00 a.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025, and operational highlights.Listeners can register for the webcast via this ...

We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on RARE. Ultragenyx Pharmaceutical Inc.'s share was trading at $23.88 as of February 9th. Zoetis (ZTS) Hits New 52-Week Low on Dismal Outlook M. A. Arkhipov/Shutterstock.com Ultragenyx Pharmaceuticals positions itself as a diversified rare disease company with four approved products generating approximately $670 million in annual ...

Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should re ...

Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.Redmile Group reported a purchase of 16,317 shares of Krystal Biotech (KRYS 0.33%) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.43 million based on quarterly average pricing.What happenedAccording to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Redmile Group increased its position in Krystal Biotech by 16 ...